Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $8.29 Analyst target: $14.25 Upside: 71.89%
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
See the full interactive analysis & chart →Informational only — not investment advice.